Results 121 to 130 of about 56,030 (266)

The SCAPE preservation lifecycle [PDF]

open access: yesIEEE/ACM Joint Conference on Digital Libraries, 2014
Kresimir Duretec   +5 more
openaire   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló   +5 more
wiley   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

A STUDY OF BIONOMY OF THE PRIVET SAWFLY (Macrophya punctumalbum (L.)) (Hymenoptera, Tenthredinidae) – A PEST OF PARK PLANTS

open access: yesActa Scientiarum Polonorum: Hortorum Cultus, 2009
The study of the bionomy of privet sawfly (Macrophya punctumalbum (L.), a pest of park plants in the city of Poznań, was conducted during three vegetation seasons in the years 1981–1983, at the insectarium of the Department of Entomology at Agricultural 
Hanna Piekarska-Boniecka   +2 more
doaj  

Through the lens of marketing authorization holders: experience in use of real‐world data and real‐world evidence in drug development and regulatory submissions in EU

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The aim of this study was to assess the general and product‐specific experiences of MAHs use of RWD/RWE in medicines development and in their regulatory submissions, and to explore organizational aspects of MAHs related to RWD/RWE. Methods An electronic survey was conducted, and information collected directly from MAHs.
Sini M. Eskola   +5 more
wiley   +1 more source

Active surveillance of drug safety in healthcare data: Sequential monitoring of bacterial and serious urinary tract infection risk in sodium‐glucose cotransporter 2 inhibitor users

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Introduction Active surveillance of adverse events using healthcare data is emerging as complementary to the monitoring of spontaneous reports and stand‐alone pharmacoepidemiologic studies. The risk of urinary tract infections (UTIs) was listed as a special warning for sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) when marketed in Europe
Haoxin Le   +5 more
wiley   +1 more source

Academic misconduct appeal services in China: Platform logics, self‐platformization and implications for integrity education

open access: yesBritish Educational Research Journal, EarlyView.
Abstract Academic misconduct appeal services have quietly emerged within China's education marketplace, with commercial agencies promoting themselves on social media to assist international students facing misconduct hearings. While existing research on academic integrity has emphasized prevention and detection, far less attention has been paid to what
Gengyan Tang   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy